Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target
December 19, 2025 — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is in the spotlight today after announcing additional financing tied to its planned Bluejay Therapeutics acquisition and drawing bullish analyst commentary that helped power a sharp move in the stock. As of the latest reported trade on Friday, December 19, 2025, MIRM was trading around $76.71, up about 9.15% from the prior close, after touching an intraday high near $77.19. What’s driving Mirum Pharmaceuticals stock today Two catalysts are dominating the narrative on 19.12.2025: That combination—fresh capital + pipeline-driven upgrade energy—is the kind of fuel that can move a mid-cap biotech
